![](https://danskbiotek.dk/wp-content/uploads/2021/02/Udklip-4-300x76.jpg)
Y-mAbs Announces Partnership Regarding Early Access Program for DANYELZA (naxitamab-gqgk) in Europe 21 December 2022
NEW YORK, Dec. 21, 2022 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or... Read more
NEW YORK, Dec. 21, 2022 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or... Read more
NEW YORK, Dec. 16, 2022 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or... Read more
Formand for Trial Nation Thomas Kongstad Petersen havde gerne set, at SVM-regeringen havde finansieringen... Read more
Copenhagen, Denmark, 15 December 2022 – MinervaX ApS, a privately held Danish biotechnology company... Read more
NEW YORK, Dec. 14, 2022 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or... Read more
NEW YORK, Dec. 08, 2022 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or... Read more
NEW YORK, Dec. 06, 2022 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or... Read more
NEW YORK, Dec. 01, 2022 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or... Read more
Oslo Norway, November 18, 2022. The LINK Medical Board is pleased to announce the appointment of Sissel... Read more